Affiliation:
1. Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy
2. Department of Pharmacy Practice
3. Detroit Receiving Hospital and University Health Center
4. School of Medicine, Wayne State University
5. Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York
6. John D. Dingell Veterans Affairs Medical Center, Detroit, Michigan
Abstract
ABSTRACT
The potential for resistance development in
Streptococcus pneumoniae
secondary to exposure to gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin at various levels was examined at high inoculum (10
8.5
to 10
9
log
10
CFU/ml) over 96 h in an in vitro pharmacodynamic (PD) model using two fluoroquinolone-susceptible isolates. The pharmacokinetics of each drug was simulated to provide a range of free areas under the concentration-time curves (
f
AUC) that correlated with various fluoroquinolone doses. Potential first (
parC
and
parE
)- and second-step (
gyrA
and
gyrB
) mutations in isolates with raised MICs were identified by sequence analysis. PD models simulating
f
AUC/MICs of 51 and ≤60, 34 and 37, ≤82 and ≤86, and ≤24 for gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin, respectively, against each isolate were associated with first-step
parC
(S52G, S79Y, and N91D) and second-step
gyrA
(S81Y and S114G) mutations. For each fluoroquinolone a delay of first- and second-step mutations was observed with increasingly higher
f
AUC/MIC ratios and recovery of topoisomerase mutations in
S. pneumoniae
was related to the
f
AUC/MIC exposure. Clinical doses of gatifloxacin, gemifloxacin, and moxifloxacin exceeded the
f
AUC/MIC resistance breakpoint against wild-type
S. pneumoniae
, whereas those of levofloxacin (500 and 750 mg) were associated with first- and second-step mutations. The exposure breakpoints for levofloxacin were significantly different (
P
< 0.001) from those of the newer fluoroquinolones gatifloxacin, gemifloxacin, and moxifloxacin. Additionally, moxifloxacin breakpoints were significantly lower (
P
< 0.002) than those of gatifloxacin. The order of resistance development determined from
f
AUC/MIC breakpoints was levofloxacin > gatifloxacin > moxifloxacin = gemifloxacin, which may be related to structural differences within the class.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献